Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors

Published:2020-12 Issue: Volume:150 Page:76-82
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Chu Xiangling,Zhao Jing,Zhou Juan,Zhou Fei,Jiang Tao,Jiang Sen,Sun Xiwen,You Xiaofang,Wu Fengying,Ren Shengxiang,Zhou Caicun,Su Chunxia

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer With PD-L1 tumor proportion score of 50% or greater;R-AD;J. Clin. Oncol.,2019

2. Garon MMDHNARea: five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 Study;Edward;J. Clin. Oncol.,2019

3. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases;Vokes;Ann. Oncol.,2018

4. Immune checkpoint inhibitor toxicity in 2018;Johnson;JAMA,2018

5. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis;Nishino;JAMA Oncol.,2016

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy;Human Vaccines & Immunotherapeutics;2024-09-13

2. Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors;Hepatology Communications;2024-08-26

3. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors;World Journal of Clinical Oncology;2024-08-24

4. Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer;Clinical and Translational Oncology;2024-08-14

5. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab;Acta Oncologica;2024-08-11